MA28774B1 - Forme de dosage solide d'heparine mouillee - Google Patents

Forme de dosage solide d'heparine mouillee

Info

Publication number
MA28774B1
MA28774B1 MA29506A MA29506A MA28774B1 MA 28774 B1 MA28774 B1 MA 28774B1 MA 29506 A MA29506 A MA 29506A MA 29506 A MA29506 A MA 29506A MA 28774 B1 MA28774 B1 MA 28774B1
Authority
MA
Morocco
Prior art keywords
heparin
wet
dosing form
pharmaceutical composition
solid dosing
Prior art date
Application number
MA29506A
Other languages
English (en)
Inventor
Shingai Majuru
Brahma Singh
Nikhil Dhoot
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of MA28774B1 publication Critical patent/MA28774B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique solide (telle qu'une forme de dosage solide) comprenant un agent d'administration et de l'héparine mouillée. L'inclusion d'héparine mouillée provoque, dans la composition pharmaceutique solide, beaucoup plus qu'une héparine non mouillée, une administration accrue de l'héparine. Sans aucun lien avec une théorie particulaire, les inventeurs estiment que du fait que la chaîne polymère d'héparine mouillée est déjà une forme « ouverte », alors que l'héparine non mouillée ne l'est pas, moins d'héparine mouillée est décomposée dans le tractus gastro-intestinal et est plus facilement absorbée dans l'estomac.
MA29506A 2004-05-06 2006-12-04 Forme de dosage solide d'heparine mouillee MA28774B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56947504P 2004-05-06 2004-05-06
US57267904P 2004-05-19 2004-05-19
US59897804P 2004-08-04 2004-08-04

Publications (1)

Publication Number Publication Date
MA28774B1 true MA28774B1 (fr) 2007-08-01

Family

ID=35320730

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29506A MA28774B1 (fr) 2004-05-06 2006-12-04 Forme de dosage solide d'heparine mouillee

Country Status (14)

Country Link
US (1) US8039018B2 (fr)
EP (1) EP1750729A2 (fr)
JP (1) JP2007536268A (fr)
KR (1) KR20070008720A (fr)
AU (1) AU2005240206B2 (fr)
BR (1) BRPI0510226A (fr)
CA (1) CA2564866A1 (fr)
EC (1) ECSP067050A (fr)
IL (1) IL178846A0 (fr)
MA (1) MA28774B1 (fr)
MX (1) MXPA06012841A (fr)
NZ (1) NZ550894A (fr)
RU (1) RU2006138703A (fr)
WO (1) WO2005107773A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551196A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
EP2211842B1 (fr) * 2007-10-24 2015-08-12 MannKind Corporation Une formulation de poudre sèche inhalable comprenant de glp-1 pour l'utilisation dans le traitement de l'hyperglycémie et du diabète par administration pulmonaire
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
BR112012020185A2 (pt) * 2010-02-04 2017-07-04 Lowell Parsons C uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
EP3542790B1 (fr) 2012-03-22 2023-09-13 Novo Nordisk A/S Compositions comprenant un agent d'administration et leur préparation
DK2827845T3 (en) * 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN118647386A (zh) * 2021-12-06 2024-09-13 广州大洲生物医药科技有限公司 肝素的口服递送

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510561A (en) * 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6331318B1 (en) * 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6610329B2 (en) * 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
US20040062773A1 (en) * 1993-04-22 2004-04-01 Emisphere Technologies Inc. Compositions for the delivery of antigens
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
SI9720025A (sl) * 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
CA2258264A1 (fr) * 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Parfums microencapsules et leur procede de production
CA2243643A1 (fr) * 1996-11-18 1998-05-28 Susan Haas Procede et composition pour induire une tolerance orale chez les mammiferes
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6358504B1 (en) * 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IN186245B (fr) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
DE69917609T2 (de) * 1998-03-05 2005-06-09 Phares Pharmaceutical Research N.V., Curaçao Arzneimittel und deren verwendung
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6440929B1 (en) * 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
NZ509239A (en) * 1998-07-27 2002-10-25 Emisphere Tech Inc 2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
CA2358463A1 (fr) * 1999-01-08 2000-07-13 Virginia Commonwealth University Agents d'administration polymeres et composes d'agents d'administration
CA2361716C (fr) * 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Procede de preparation de salicylamides alkyles
ATE311373T1 (de) 1999-02-11 2005-12-15 Emisphere Tech Inc Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
MXPA01008611A (es) * 1999-02-26 2003-06-24 Emisphere Tech Inc Compuestos y composiciones para suministrar agentes activos.
EP1175390B1 (fr) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
KR100788970B1 (ko) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 페녹시 카르복시산 화합물 및 조성물
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
ES2298168T3 (es) * 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6384278B1 (en) * 2000-02-04 2002-05-07 Emisphere Technologies, Inc. Boron-mediated amidation of carboxylic acids
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2386263T3 (es) 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
WO2001092206A1 (fr) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Procede de preparation de salicylamides
JP2004521857A (ja) 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
JP4707931B2 (ja) * 2000-08-18 2011-06-22 エミスフェアー・テクノロジーズ・インク 活性剤デリバリー用化合物および組成物
WO2002016309A1 (fr) 2000-08-18 2002-02-28 Emisphere Technologies, Inc. Composes et compositions permettant de distribuer des agents actifs
NZ524138A (en) 2000-09-06 2004-12-24 Emisphere Tech Inc Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2002019969A2 (fr) 2000-09-06 2002-03-14 Emisphere Technologies Inc. Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
CA2438849A1 (fr) 2001-03-01 2002-09-12 Emisphere Technologies, Inc. Composes et compositions servant a administrer des agents actifs
US20030225300A1 (en) * 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
BRPI0411165A (pt) * 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso

Also Published As

Publication number Publication date
CA2564866A1 (fr) 2005-11-17
ECSP067050A (es) 2007-02-28
US20070224262A1 (en) 2007-09-27
NZ550894A (en) 2011-02-25
RU2006138703A (ru) 2008-06-20
AU2005240206A1 (en) 2005-11-17
WO2005107773A3 (fr) 2006-01-05
US8039018B2 (en) 2011-10-18
MXPA06012841A (es) 2007-02-15
WO2005107773A2 (fr) 2005-11-17
IL178846A0 (en) 2007-05-15
BRPI0510226A (pt) 2007-10-23
JP2007536268A (ja) 2007-12-13
WO2005107773A8 (fr) 2006-12-21
AU2005240206B2 (en) 2011-04-07
KR20070008720A (ko) 2007-01-17
EP1750729A2 (fr) 2007-02-14

Similar Documents

Publication Publication Date Title
MA28774B1 (fr) Forme de dosage solide d'heparine mouillee
US20130273154A1 (en) Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US20160235745A1 (en) Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof
EP1804717A4 (fr) Revetement d'administration de medicament pouvant etre utilise avec une endoprothese vasculaire
AU2007230234A1 (en) Use of polymeric materials with other substances for improved performance
DE69122751D1 (de) Arzneimittelzusammensetzung mit kontrollierter wirkstoffabgabe
CA2561649C (fr) Compositions pharmaceutiques comprimees comprenant peg et des electrolytes
MA29681B1 (fr) Formes galeniques du risedronate
EP2609950A3 (fr) Dispositif médical pour l'administration d'une solution
EP1366760A4 (fr) Comprimes a dissolution rapide dans la cavite buccale
WO2007075475A3 (fr) Formes pharmaceutiques resistantes au reflux gastrique
EP1670838A4 (fr) Copolymere sequence amphiphile et composition polymere comprenant celui-ci pour l'administration de medicaments
EP2540294A4 (fr) Préparation solide à libération prolongée pour usage oral
GB2342357A (en) Amphiphilic polysaccharide derivatives
Oren et al. Indomethacin-induced colonic ulceration and bleeding
KR970064597A (ko) 위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물
JPH0142927B2 (fr)
Feriani et al. Peritoneal dialysis solutions and systems
Oh et al. What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?
WO2003037296A3 (fr) Methodes et formes posologiques permettant d'ameliorer la biodisponibilite d'agents therapeutiques
CA2551043A1 (fr) Utilisation de cystine ou de cysteine dans la prevention et le traitement du stress oxydatif cause par l'hemodialyse et des nephropathies chroniques ou aigues
FR2387032A1 (fr) Composition pharmaceutique pour l'administration orale de pancreatine
EP2044931A3 (fr) Compositions pharmaceutiques basées sur des zéolithes poreux en tant que supports de libération de molécules actives pharmacologiquement et utilisation associée
CN207912958U (zh) 一种肠道水疗机
Morelle Diclofenac/tenofovir disoproxil fumarate interaction